1. CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy
- Author
-
Hyeonjeong Kang, Housheng Hansen He, Mark D. Minden, Li Zhang, Jong Bok Lee, Yong Zeng, Dalam Ly, Enoch Tin, Fraser Soares, Nayeema Akhtar, Branson Chen, and Musaddeque Ahmed
- Subjects
0301 basic medicine ,Adoptive cell transfer ,Myeloid ,T-Lymphocytes ,T cell ,Chronic lymphocytic leukemia ,Immunology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Mice, Inbred NOD ,hemic and lymphatic diseases ,medicine ,Animals ,Humans ,CRISPR ,Cells, Cultured ,Predictive marker ,Gene Expression Regulation, Leukemic ,business.industry ,Receptors, IgG ,Myeloid leukemia ,Cell Biology ,Hematology ,medicine.disease ,Adoptive Transfer ,Leukemia, Myeloid, Acute ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,Female ,CRISPR-Cas Systems ,business - Abstract
Acute myeloid leukemia (AML) remains a devastating disease in need of new therapies to improve patient survival. Targeted adoptive T-cell therapies have achieved impressive clinical outcomes in some B-cell leukemias and lymphomas but not in AML. Double-negative T cells (DNTs) effectively kill blast cells from the majority of AML patients and are now being tested in clinical trials. However, AML blasts obtained from ∼30% of patients show resistance to DNT-mediated cytotoxicity; the markers or mechanisms underlying this resistance have not been elucidated. Here, we used a targeted clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screen to identify genes that cause susceptibility of AML cells to DNT therapy. Inactivation of the Spt-Ada-Gcn5-acetyltransferase (SAGA) deubiquitinating complex components sensitized AML cells to DNT-mediated cytotoxicity. In contrast, CD64 inactivation resulted in resistance to DNT-mediated cytotoxicity. Importantly, the level of CD64 expression correlated strongly with the sensitivity of AML cells to DNT treatment. Furthermore, the ectopic expression of CD64 overcame AML resistance to DNTs in vitro and in vivo. Altogether, our data demonstrate the utility of CRISPR/Cas9 screens to uncover mechanisms underlying the sensitivity to DNT therapy and suggest CD64 as a predictive marker for response in AML patients.
- Published
- 2021